Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSattva S. NeelapuMFMoshe FridmanJWJacob Wulff

Discussion

Loading...

Member takes

Overview

Multicenter phase 2 trial shows complete response predicts long-term progression-free survival in high-risk large B cell lymphoma patients, suggesting surrogate endpoints for future studies.

Key Points

  • To assess the prognostic role of surrogate endpoints on long-term outcomes in high-risk large B cell lymphoma patients treated with axicabtagene ciloleucel.
  • Evaluated patients with high-risk large B-cell lymphoma in a multicenter phase 2 study
  • Assessed response rates and long-term outcomes using Kaplan-Meier and Cox regression analyses
  • Analyzed correlations between complete response at 6 months and event-free survival, progression-free survival, overall survival, and duration of response
  • 86% complete response rate observed in treated patients after 6 months
  • At 36 months, event-free survival was 88.9% for patients achieving complete response vs 30.0% for non-responders
  • Complete response at 6 months significantly associated with improved long-term outcomes for event-free survival, progression-free survival, and overall survival

Cite This Study

Neelapu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df49https://doi.org/10.1182/blood-2025-3717
View Full Paper
Ask AI
Bookmark
Share